Psychemedics (PMDI) 10-K 26 Mar 21 2020 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Mar. 26, 2021	Jun. 30, 2020
Document Information [Line Items]
Entity Registrant Name	PSYCHEMEDICS CORP
Entity Central Index Key	0000806517
Trading Symbol	pmd
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Interactive Data Current	Yes
Entity Common Stock, Shares Outstanding (in shares)		5,536,493
Entity Public Float			$ 22
Entity Shell Company	false
Document Type	10-K
Document Period End Date	Dec. 31, 2020
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Title of 12(b) Security	Common stock. $0.005 par value

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Current Assets:
Cash and cash equivalents	$ 2,833,000	$ 7,283,000
Accounts receivable, net of allowance for doubtful accounts of $37 and $45 at December 31, 2020 and 2019, respectively	3,356,000	3,780,000
Prepaid expenses and other current assets	914,000	1,306,000
Income tax receivable	2,495,000	482,000
Total Current Assets	9,598,000	12,851,000
Property and equipment:
Computer software	4,422,000	4,166,000
Office furniture and equipment	2,139,000	2,124,000
Laboratory equipment	15,978,000	16,195,000
Leasehold improvements	3,629,000	4,574,000
Property and equipment	26,168,000	27,059,000
Accumulated depreciation and amortization	(16,937,000)	(16,197,000)
Property and equipment, net	9,231,000	10,862,000
Other assets	888,000	943,000
Operating lease right-of-use assets	4,286,000	2,875,000
Total Assets	24,003,000	27,531,000
Current Liabilities:
Accounts payable	577,000	617,000
Accrued expenses	1,801,000	3,577,000
Current portion of long-term debt	688,000	678,000
Current portion of operating lease liabilities	875,000	963,000
Total Current Liabilities	3,941,000	5,835,000
Long-term debt	3,444,000	1,951,000
Deferred tax liabilities, long-term	211,000	550,000
Long-term portion of operating lease liabilities	3,895,000	2,375,000
Total Liabilities	11,491,000	10,711,000
Commitments and Contingencies (Note 9)
Shareholders' Equity:
Preferred stock, $0.005 par value, 873 shares authorized,no shares issued or outstanding
Common stock, $0.005 par value; 50,000 shares authorized 6,205 shares and 6,185 shares issued at December 31, 2020 and 2019, respectively, 5,537 shares outstanding and 5,517 shares outstanding at December 31, 2020 and 2019, respectively	31,000	31,000
Additional paid-in capital	32,803,000	32,249,000
Less - Treasury stock, at cost, 668 shares	(10,082,000)	(10,082,000)
Accumulated deficit	(8,606,000)	(3,754,000)
Accumulated other comprehensive loss	(1,634,000)	(1,624,000)
Total Shareholders' Equity	12,512,000	16,820,000
Total Liabilities and Shareholders' Equity	$ 24,003,000	$ 27,531,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) shares in Thousands, $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Allowance for doubtful accounts	$ 37	$ 45
Preferred stock, par value (in dollars per share)	$ 0.005	$ 0.005
Preferred stock, shares authorized (in shares)	873	873
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.005	$ 0.005
Common stock, shares authorized (in shares)	50,000	50,000
Common stock, shares issued (in shares)	6,205	6,185
Common stock, shares outstanding (in shares)	5,537	5,517
Treasury stock, shares (in shares)	668	668

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues	$ 21,360	$ 37,678	$ 42,674
Cost of revenues	16,474	21,234	22,056
Gross profit	4,886	16,444	20,618
Operating Expenses:
General & administrative	6,095	7,221	6,430
Marketing & selling	3,577	4,658	5,027
Research & development	1,280	1,567	1,551
Total Operating Expenses	10,952	13,446	13,008
Operating (loss) income	(6,066)	2,998	7,610
Other (expense) income	(140)	58	43
Net (loss) income before provision for income taxes	(6,206)	3,056	7,653
(Benefit from) provision for income taxes	(2,347)	1,514	3,069
Net (loss) income	(3,859)	1,542	4,584
Other Comprehensive (Loss) Income:
Foreign currency translation, net of taxes	(10)	(225)	(1,161)
Total Comprehensive (Loss) Income	$ (3,869)	$ 1,317	$ 3,423
Basic net income (loss) per share (in dollars per share)	$ (0.70)	$ 0.28	$ 0.83
Diluted net income (loss) per share (in dollars per share)	(0.70)	0.28	0.83
Dividends declared, per share (in dollars per share)	$ 0.18	$ 0.72	$ 0.69
Weighted average common shares outstanding:
Basic (in shares)	5,524	5,514	5,502
Diluted (in shares)	5,524	5,525	5,547

Consolidated Statements of Shar

Consolidated Statements of Shareholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2017	6,160		668
Balance at Dec. 31, 2017	$ 31	$ 31,022	$ (10,082)	$ (2,113)	$ (238)	$ 18,620
Shares issued – vested (in shares)	15
Shares issued – vested
Tax withholding related to vested shares from employee stock plans		(93)				(93)
Stock compensation expense		594				594
Cash dividends declared				(3,797)		(3,797)
Net income (loss)				4,584		4,584
Foreign currency translation, net of taxes					(1,161)	(1,161)
Balance (in shares) at Dec. 31, 2018	6,175		668
Balance at Dec. 31, 2018	$ 31	31,523	$ (10,082)	(1,326)	(1,399)	18,747
Shares issued – vested (in shares)	10
Shares issued – vested
Tax withholding related to vested shares from employee stock plans		(33)				(33)
Stock compensation expense		759				759
Cash dividends declared				(3,970)		(3,970)
Net income (loss)				1,542		1,542
Foreign currency translation, net of taxes					(225)	(225)
Balance (in shares) at Dec. 31, 2019	6,185		668
Balance at Dec. 31, 2019	$ 31	32,249	$ (10,082)	(3,754)	(1,624)	16,820
Shares issued – vested (in shares)	20
Shares issued – vested
Tax withholding related to vested shares from employee stock plans		(9)				(9)
Stock compensation expense		563				563
Cash dividends declared				(993)		(993)
Net income (loss)				(3,859)		(3,859)
Foreign currency translation, net of taxes					(10)	(10)
Balance (in shares) at Dec. 31, 2020	6,205		668
Balance at Dec. 31, 2020	$ 31	$ 32,803	$ (10,082)	$ (8,606)	$ (1,634)	$ 12,512

Consolidated Statements of Sh_2

Consolidated Statements of Shareholders' Equity (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Dividends declared, per share (in dollars per share)	$ 0.18	$ 0.72	$ 0.69

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities:
Net income (loss)	$ (3,859,000)	$ 1,542,000	$ 4,584,000
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization	2,691,000	2,914,000	3,063,000
ROU asset amortization	935,000
Deferred income taxes	(339,000)	(405,000)	(288,000)
Loss on sale of fixed assets	94,000		6,000
Non-cash interest income (expense)		33,000	(41,000)
Stock compensation expense	563,000	759,000	594,000
Changes in operating assets and liabilities:
Accounts receivable	424,000	1,049,000	(355,000)
Prepaid expenses and other current assets	392,000	64,000	145,000
Income tax receivable	(2,013,000)	(482,000)
Accounts payable	(281,000)	(494,000)	77,000
Operating lease liabilities	(914,000)
Accrued expenses	(1,776,000)	(671,000)	144,000
Net cash (used in) provided by operating activities	(4,083,000)	4,309,000	7,929,000
Cash flows from investing activities:
Purchases of investments in short-term investments			(4,035,000)
Proceeds from sale of fixed assets	140,000
Proceeds from short-term investments		3,810,000
Other assets	(7,000)	(56,000)	(133,000)
Purchases of property and equipment and capitalized software development costs	(991,000)	(1,677,000)	(1,191,000)
Net cash (used in) provided by investing activities	(858,000)	2,077,000	(5,359,000)
Cash flows from financing activities:
Cash dividends paid	(993,000)	(3,970,000)	(3,797,000)
Proceeds from issuance of stock, net of tax withholding	(9,000)	(33,000)	(93,000)
Payments of equipment financing	(678,000)	(415,000)	(1,749,000)
Net cash provided by (used in) financing activities	501,000	(3,002,000)	(5,639,000)
Effect of exchange rate changes on cash	(10,000)	(170,000)	(1,027,000)
Net (decrease) increase in cash and cash equivalents	(4,450,000)	3,214,000	(4,096,000)
Cash and cash equivalents, beginning of year	7,283,000	4,069,000	8,165,000
Cash and cash equivalents, end of year	2,833,000	7,283,000	4,069,000
Supplemental disclosures of cash flow information:
Cash paid for income taxes	249,000	2,898,000	3,743,000
Cash paid for interest	75,000	59,000	108,000
Cash paid for operating leases	1,038,000	1,199,000	994,000
Right-of-use assets acquired through operating leases	2,346,000	4,363,000
Non-cash investing and financing activities:
Purchases of equipment through accounts payable and accrued liabilities	241,000	1,882,000	207,000
Paycheck Protection Program CARES Act [Member]
Cash flows from financing activities:
Proceeds from long term det	2,181,000
Equipment Loan Arrangement [Member]
Cash flows from financing activities:
Proceeds from long term det		$ 1,416,000

Note 1 - Nature of Business

Note 1 - Nature of Business	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Company Overview Psychemedics Corporation (the “Company”) provides hair testing for drugs of abuse, utilizing a patented hair analysis method involving digestion of hair, enzyme immunoassay and mass spectrometry to analyze hair to detect abused substances. The Company's customers include Fortune 500 COVID- 19 The outbreak of coronavirus (“COVID- 19” 19 19's 19, The Coronavirus Aid, Relieve and Economic Security Act (“CARES”) Act, enacted on March 27, 2020, 19. 19 $2.1 December 31, 2020, 2021 2022 2020 Liquidity and Management's Plans At December 31, 2020, $2.8 12 may not no

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Significant Accounting Policies [Text Block]	2. Risks and Uncertainties The Company is subject to a number of risks and uncertainties similar to those of other companies, such as those associated with the continued expansion of the Company's sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered by the Company, the economic health of principal customers of the Company, financial and operational risks associated with expansion of testing facilities used by the Company, government regulation (including, but not Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates, including those related to bad debts, long-lived asset lives, income tax valuation and share based compensation, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known. Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities at the date of purchase of 90 December 31, 2020 2019, no Property and Equipment Property & equipment are recorded at cost. Depreciation and amortization is computed over the estimated useful lives of the assets, using the straight-line method. Repair and maintenance costs are expensed as incurred. The estimated useful lives of the assets are: Computer software (years) 3 to 5 Office furniture and equipment (years) 3 to 7 Laboratory equipment 5 to 7 Leasehold improvements Lesser of estimated useful life or lease term The Company recorded depreciation and amortization related to property and equipment and capitalized software of $2.6 $2.9 $3.1 2020, 2019 2018 $0.8 not December 31, 2020. Capitalized Software Development Costs We capitalize costs related to significant software projects developed or obtained for internal use, including costs incurred in a cloud computing arrangement. Costs incurred during the preliminary project work stage or conceptual stage, such as determining the performance requirements, system requirements and data conversion, are expensed as incurred. Costs incurred in the application development phase, such as coding, testing for new software and upgrades that result in additional functionality, are capitalized and are amortized using the straight-line method over the useful life of the software for 5 December 31, 2020 2019, $213 $234 $293 $457 $525 2020, 2019 2018, may Other Assets Other assets primarily consist of capitalized legal costs relating to patent applications. The Company amortizes these costs over the lesser of the legal life or estimated useful life of the patent from the date of grant of the applicable patent. The typical life is twenty December 31, 2020, $1.0 $0.3 $0.7 December 31, 2019, $1.0 $0.3 $0.7 $62 $40 $38 2020, 2019 2018, $65 five Revenue Recognition The Company is in the business of performing drug testing services and reporting the results thereof. The Company's services are primarily drug and alcohol testing for its customers for an agreed-upon fee per unit tested. The revenues are recognized when the drug test is performed and reported to the customer. On January 1, 2018, 606, “Revenue from Contracts with Customers” 606” 606 not Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration ( none 30 60 The table below disaggregates our external revenue by major source (in thousands). For additional revenue detail relating to geographic breakdown of sales, see Note 14 Year Ended December 31, 2020 2019 2018 Consolidated Revenue: Testing $ 19,068 $ 34,555 $ 39,174 Shipping / Collection (hair) 2,174 2,876 3,159 Other 118 247 341 Total Revenue $ 21,360 $ 37,678 $ 42,674 Testing Revenue Drug and alcohol tests for drugs of abuse using hair, performed in the Company's forensic laboratory in California, represents our primary service. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (“CCF”) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer. Most tests are completed the same day that the hair specimen is received. Substantially all tests are completed within a few days once received for processing at our laboratory in California. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue. Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. Sales taxes the Company pays concurrent with revenue-producing activities are excluded from revenue. Shipping and Hair Collection Revenue Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (“sample”) to the Company's laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by third Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. As the Company controls the service before transferring to the customer, it is considered a principal in the transaction, and therefore records revenues on gross basis, with shipping and hair collection costs in costs of revenues. Other Revenue Other revenue represents several items including; urine testing performed by other labs, medical review officer charges, legal/testifying services, and other miscellaneous charges. The total of all of these items is less than 1% Practical Expedients and Exemptions The Company generally expenses sales commissions when incurred as they are typically not Research and Development Expenses The Company expenses all research and development costs as incurred. Income Taxes The Company accounts for income taxes using the liability method pursuant to ASC 740, “Income Taxes” Concentration of Credit Risk and Off-Balance Sheet Risk The Company has no may not not not Significant Customers The Company had no 10% December 31, 2020. One 26% 31% December 31, 2019 2018, no 10% December 31, 2020. two 13% 11% December 31, 2019. Stock-Based Compensation The Company accounts for equity awards in accordance with ASC 718, Compensation — Stock Compensation” 718” 718 one not 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting no Stock compensation expense by income statement account is as follows (in thousands): Stock-Based Compensation Year Ended December 31, 2020 2019 2018 Cost of revenues $ 50 $ 59 $ 62 General & administrative 380 579 436 Marketing & selling 74 54 29 Research & development 59 67 67 Total stock compensation $ 563 $ 759 $ 594 See Note 7 Basic and Diluted Net Income per Share Basic net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares and dilutive common stock equivalents outstanding during the period. The number of dilutive common stock equivalents outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and the unvested portion of stock unit awards (“SUAs”). Basic and diluted weighted average common shares outstanding are as follows (in thousands): 2020 2019 2018 Weighted average common shares outstanding, basic 5,524 5,514 5,502 Dilutive common equivalent shares - 11 45 Weighted average common shares outstanding, assuming dilution 5,524 5,525 5,547 For the years ended December 31, 2020, 2019 2018, 588 357 86 not Financial Instruments Financial instruments include cash, accounts receivable and accounts payable. Estimated fair values of these financial instruments approximate carrying values due to their short-term nature. The Company has two 30 1.75% 3.79%. one 1% Basis of Preparation and Consolidation The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries have been prepared using accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany transactions and balances have been eliminated. Foreign Currency Translation To the extent sales are made through our Brazil subsidiary, such sales are transacted in Brazilian Real and translated into US dollars. Foreign currency denominated assets and liabilities are translated into U.S. dollars using the exchange rates in effect at the consolidated balance sheet date. Results of operations and cash flows are translated using the average exchange rates throughout the period. The effect of exchange rate fluctuations on translation of assets and liabilities that are in the functional currency is included as a component of shareholders' equity in accumulated other comprehensive income (loss). The total change in foreign currency translation adjustment for the year ended December 31, 2020 2019 $0.2 $0.2 Segment Reporting The Company manages its operations as one 14 Recently Adopted Accounting Pronouncements In February 2016, 2016 02, Leases” 2018 10, 2018 11, 2018 20 2019 01 842 12 December 15, 2018 842 January 1, 2019 ( 10 In August 2018, 2018 15, Intangibles—Goodwill and Other—Internal-Use Software: Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” 2018 15 2018 15 2020, 2018 15 January 1, 2019 no New Accounting Pronouncements In December 2019, 2019 12, Income Taxes (Topic 740 740. 740 December 15, 2020, may

Note 3 - Accounts Receivable

Note 3 - Accounts Receivable	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	3. The Company maintains an allowance for uncollectible accounts receivable based on management's assessment of the collectability of its customer accounts by reviewing customer payment patterns and other relevant factors. The Company reviews the adequacy of the allowance for uncollectible accounts on a quarterly basis and adjusts the balance as determined necessary. Write-offs are recorded at the time a customer account is deemed uncollectable. The following is a rollforward of the Company's allowance for doubtful accounts (in thousands): As of December 31, 2020 2019 Balance, beginning of period $ 45 $ 67 Provision for doubtful accounts 22 11 Write-offs (30 ) (33 ) Balance, end of period $ 37 $ 45

Note 4 - Accrued Expenses

Note 4 - Accrued Expenses	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	4. Accrued expenses consist of the following (in thousands): As of December 31, 2020 2019 Accrued compensation and employee benefits $ 315 $ 450 Accrued vacation expense 379 399 Accrued taxes 4 564 Accrued shipping expense 511 368 Accrued payables for equipment and leasehold improvements - 1,453 Other accrued expenses 592 343 Total Accrued Expenses $ 1,801 $ 3,577

Note 5 - Income Taxes

Note 5 - Income Taxes	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Income Tax Disclosure [Text Block]	5. The income tax provision consists of the following (in thousands): Year Ended December 31, 2020 2019 2018 Current – Federal $ (2,006 ) $ 1,478 $ 2,117 State (2 ) 54 119 Foreign - 348 1,122 Total Current Deferred – (2,008 ) 1,880 3,358 Federal (13 ) (139 ) (168 ) State (326 ) (227 ) (121 ) Total Deferred (339 ) (366 ) (289 ) Income Tax Provision $ (2,347 ) $ 1,514 $ 3,069 A reconciliation of the effective rate with the federal statutory rate is as follows: Year Ended December 31, 2020 2019 2018 Federal statutory rate 21.0 % 21.0 % 21.0 % State income taxes, net of federal benefit 4.4 % (4.5 %) 0.0 % Permanent differences 0.0 % (8.1 %) 0.2 % Stock based compensation (0.4 %) 1.3 % 0.1 % Federal R&D Credits 1.6 % (4.7 %) (1.7 %) Foreign taxes, net of federal benefit (2.2 %) 44.5 % 20.5 % Difference in tax rate for carryback claim 13.4 % 0.0 % 0.0 % Effective tax rate 37.8 % 49.5 % 40.1 % The change in effective tax rate from 2019 2020 December 31, 2020, no 2020 2016 December 31, 2020, $1.7 2030 2040. December 31, 2020, $0.1 2040 $1.1 2013 2020 2020, 4.4% 1.8%. The components of the net deferred tax liabilities included in the accompanying balance sheets are as follows (in thousands): As of December 31, 2020 2019 Deferred Tax Assets Allowance for doubtful accounts $ 9 $ 10 Accrued expenses 112 87 Stock-based compensation 265 195 R&D tax credits 1,005 788 Operating lease 1,130 764 PPP Loan expenses 9 - NOL Carryforward 97 - Total Deferred Tax Assets $ 2,627 $ 1,844 Deferred Tax Liabilities Excess of tax over book depreciation and amortization $ (1,775 ) $ (1,696 ) Prepaid expenses (48 ) (40 ) Operating lease (1,015 ) (658 ) Total Deferred Tax Liabilities (2,838 ) (2,394 ) Net Deferred Tax Liabilities $ (211 ) $ (550 ) Income taxes are recorded in accordance with FASB ASC Topic 740, 740” not not ASC 740 two first not second 50% may may not December 31, 2020, no December 31, 2019. The Company operates within multiple taxing jurisdictions and could be subject to audit in these jurisdictions. These audits may may December 31, 2020, 2019 2018 not 2019, 2016 December 31, 2017 December 31, 2020 The net (loss) income before income taxes was ( $6.2 $3.1 December 31, 2020 2019, $1.1 December 31, 2020 2019, 2020 no

Note 6 - Preferred Stock

Note 6 - Preferred Stock	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Preferred Stock [Text Block]	6. The Board of Directors has the authority to designate authorized preferred shares in one no

Note 7 - Stock-based Awards

Note 7 - Stock-based Awards	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Share-based Payment Arrangement [Text Block]	7. The 2006 2006 ten January 2019, 2006 850 1.2 December 31, 2020, 45 2006 The fair value of the SUAs is determined by the closing price on the date of grant. The fair value of options is determined using a Black-Scholes model. The SUAs and options vest over a period of two four 2016 09 2016, no On November 11, 2020, 190 40 December 16, 2020, one 5 two four two four 10 not No 2006 The following table represents all shares granted by the Company under the 2006 three Grant Date Type Shares Fair Value (1) December 16, 2020 SUA 5 $ 4.71 November 11, 2020 Options 40 $ 1.13 November 11, 2020 SUA 190 $ 4.07 May 3, 2019 Options 192 $ 2.99 May 3, 2019 SUA 18 $ 10.60 July 24, 2018 Options 2 $ 5.49 May 3, 2018 SUA 6 $ 21.04 May 3, 2018 Options 117 $ 5.69 ( 1 The fair value for the SUA's is the closing price of the Company's stock on that date. The fair value for options represents the fair value calculated using the Black-Scholes model. Options have contractual lives of 10 May 3, 2018 $5.69 $21.04 6.25 5.75 38% 3.4% 4.2% July 24, 2018 $5.49 $19.83 6.25 39% 3.4% 4.1% May 3, 2019 $2.99 $10.60 6.25 5.75 41% 2.4% 3.9% November 11, 2020 $1.13 $4.07 6.25 5.75 45% 0.9% 4.0% December 31, 2020, 2019, 2018, $3.47, $3.40 $2.49, December 31, 2020, 2019, 2018, $4.89, $12.01 $14.42, A summary of the Company's stock option activity is as follows (in thousands, except price per share): Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (years) Aggregate Intrinsic Value (2) Outstanding, December 31, 2019 584 $ 14.94 7.9 $ - Granted 40 $ 4.14 Exercised - - Forfeited (20 ) $ 3.21 Outstanding, December 31, 2020 604 $ 14.31 7.0 $ - Exercisable, December 31, 2020 424 $ 14.55 6.7 $ 35 ( 2 The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market price of the Company's stock on December 31 December 31, 2020 2019 $5.09 $9.15, A summary of the Company's stock unit award activity is as follows (in thousands, except price per share): Weighted Weighted Number of Average Price Average Fair Shares per Share (3) Value (3) Outstanding & Unvested, December 31, 2019 24 $ 12.84 $ 311 Granted 195 $ 4.07 $ 794 Converted to common stock (20 ) $ 13.00 $ (254 ) Cancelled (1 ) $ 20.24 $ (20 ) Forfeited (32 ) $ 5.12 $ (162 ) Outstanding & Unvested, December 31, 2020 166 $ 4.50 $ 745 ( 3 Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each transaction type. The weighted average fair value is the weighted average share price times the number of shares. The fair value of stock unit award vesting was $274 $223 $308 December 31, 2020, 2019 2018, $115 $144 $493 December 31, 2020, 2019 2018, As of December 31, 2020, 815 2006 December 31, 2020, $1.1 3.1

Note 8 - Employee Benefit Plan

Note 8 - Employee Benefit Plan	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	8. The Psychemedics Corporation 401 “401 401 21 401 may, not $198 $262 $264 December 31, 2020, 2019 2018,

Note 9 - Commitments and Contin

Note 9 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	9. Commitments The Company leases certain of its facilities and equipment under operating lease agreements expiring on various dates through December 2026. $1.1 $1.2 $1.0 2020, 2019 2018, 10 Contingencies The Company is subject legal proceedings and claims in the ordinary course of its business. The Company believes that although there can be no not

Note 10 - Operating Leases

Note 10 - Operating Leases	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Lessee, Operating Leases [Text Block]	10. The Company has five no not not As of December 31, 2019, $2.9 $3.3 842. December 31, 2020 3.9%. December 31, 2020 4.9 twelve December 31, 2020 2019, $1.1 $1.2 Maturities and balance sheet presentation of the Company's lease liabilities for all operating leases as of December 31, 2020 2021 $ 1,041 2022 1,028 2023 1,096 2024 1,035 2025 593 2026 458 Total Lease Payments 5,251 Less Interest: (481 ) Present value of lease liabilities $ 4,770 Current operating lease liabilities $ 875 Long-term operating lease liabilities 3,895 Total $ 4,770

Note 11 - Debt and Other Financ

Note 11 - Debt and Other Financing Arrangements	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Debt Disclosure [Text Block]	11. On March 20, 2014, August 8, 2014, September 15, 2015, October 30, 2017, December 2, 2019, $16 60 October 30, 2017 30 1.75% December 2, 2019 3.79%. 60 first On November 2, 2020, amended the Equipment Loan Arrangement in order to, among other things, waive, for the quarters ended December 31, 2020, March 31, 2021 June 30, 2021, $1,500,000 $1 fourth 2020 $225,000 first second 2021. November 1, 2020 June 30, 2021. may 12 September 30, 2020. not December 31, 2020. On March 23, 2021, June 30, 2021. The Waiver and Amendment amended the Equipment Loan Arrangement in order to, among other things, waive the minimum required EBITDA of $1 fourth 2020. first 2021 $225,000 $1. December 31, 2020 $3.1 Under the Equipment Loan Arrangement, the Company executed notes on March 24, 2014, May 22, 2014, June 13, 2014, August 8, 2014, September 15, 2015, March 23, 2016, November 10, 2017, December 4, 2019 $1.1 $1.9 $3.0 $1.0 $1.1 $610 $2.1 $1.4 $12.2 $0.7 $0.4 2020 2019, December 31, 2020, November 10, 2017 December 4, 2019 2018. December 31, 2020 3% $75 December 31, 2020, 3%. On May 1, 2020, $2,181,157, May 4, 2022. one 1% six no 2021. The annual principal repayment requirements for debt obligations as of December 31, 2020 2021 $ 688 2022 664 2023 294 2024 305 Long-term debt from equipment financing 1,951 Less current portion of long-term debt from equipment financing (688 ) Long-term debt from equipment financing, net of current portion 1,263 PPP Loan 2,181 Total long-term debt, net of current portion $ 3,444

Note 12 - Selected Quarterly Fi

Note 12 - Selected Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Quarterly Financial Information [Text Block]	12. The following are selected quarterly financial data for the years ended December 31, 2020 2019 Quarter Ended - 2020 MAR 31 JUN 30 SEP 30 DEC 31 Revenues $ 7,537 $ 3,314 $ 5,174 $ 5,335 Gross profit 2,728 (252 ) 1,133 1,277 Loss from operations (242 ) (3,306 ) (1,409 ) (1,109 ) Net loss (159 ) (2,050 ) (1,107 ) (543 ) Basic net loss per share $ (0.03 ) $ (0.37 ) $ (0.20 ) $ (0.10 ) Diluted net loss per share $ (0.03 ) $ (0.37 ) $ (0.20 ) $ (0.10 ) Quarter Ended - 2019 MAR 31 JUN 30 SEP 30 DEC 31 Revenues $ 9,822 $ 9,289 $ 9,852 $ 8,715 Gross profit 4,408 4,169 4,382 3,485 Income (loss) from operations 944 1,326 1,334 (606 ) Net income (loss) 627 768 677 (530 ) Basic net income (loss) per share $ 0.11 $ 0.14 $ 0.12 $ (0.09 ) Diluted net income (loss) per share $ 0.11 $ 0.14 $ 0.12 $ (0.09 )

Note 13 - Other Expense

Note 13 - Other Expense	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Other Income and Other Expense Disclosure [Text Block]	13. Other expense consists primarily of interest expense related to the Company's equipment financing arrangement. Interest expense for the year ended December 31, 2020, 2019 2018 $75 $59 $106 no December 31, 2020. December 31, 2019 2018 $134 $149

Note 14 - Business Segment Repo

Note 14 - Business Segment Reporting	12 Months Ended
	Dec. 31, 2020
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	14. The Company manages its operations as one one Year Ended December 31, 2020 2019 2018 Consolidated Revenue: United States $ 19,486 $ 27,329 $ 29,189 Brazil 1,344 9,819 13,046 Other 530 530 439 Total Revenue $ 21,360 $ 37,678 $ 42,674 All the Company's operations are in the United States. The Company's assets by geographic region are as follows (in thousands): As of December 31, Assets: 2020 2019 United States $ 24,003 $ 27,091 Brazil - 440 Total Assets $ 24,003 $ 27,531

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2020
Accounting Policies [Abstract]
Risks and Uncertainties [Policy Text Block]	Risks and Uncertainties The Company is subject to a number of risks and uncertainties similar to those of other companies, such as those associated with the continued expansion of the Company's sales and marketing network, technological developments, intellectual property protection, development of markets for new products and services offered by the Company, the economic health of principal customers of the Company, financial and operational risks associated with expansion of testing facilities used by the Company, government regulation (including, but not
Use of Estimates, Policy [Policy Text Block]	Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates, including those related to bad debts, long-lived asset lives, income tax valuation and share based compensation, and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with original maturities at the date of purchase of 90 December 31, 2020 2019, no
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property & equipment are recorded at cost. Depreciation and amortization is computed over the estimated useful lives of the assets, using the straight-line method. Repair and maintenance costs are expensed as incurred. The estimated useful lives of the assets are: Computer software (years) 3 to 5 Office furniture and equipment (years) 3 to 7 Laboratory equipment 5 to 7 Leasehold improvements Lesser of estimated useful life or lease term The Company recorded depreciation and amortization related to property and equipment and capitalized software of $2.6 $2.9 $3.1 2020, 2019 2018 $0.8 not December 31, 2020.
Research, Development, and Computer Software, Policy [Policy Text Block]	Capitalized Software Development Costs We capitalize costs related to significant software projects developed or obtained for internal use, including costs incurred in a cloud computing arrangement. Costs incurred during the preliminary project work stage or conceptual stage, such as determining the performance requirements, system requirements and data conversion, are expensed as incurred. Costs incurred in the application development phase, such as coding, testing for new software and upgrades that result in additional functionality, are capitalized and are amortized using the straight-line method over the useful life of the software for 5 December 31, 2020 2019, $213 $234 $293 $457 $525 2020, 2019, 2018, may
Other Assets [Policy Text Block]	Other Assets Other assets primarily consist of capitalized legal costs relating to patent applications. The Company amortizes these costs over the lesser of the legal life or estimated useful life of the patent from the date of grant of the applicable patent. The typical life is twenty December 31, 2020, $1.0 $0.3 $0.7 December 31, 2019, $1.0 $0.3 $0.7 $62 $40 $38 2020, 2019 2018, $65 five
Revenue [Policy Text Block]	Revenue Recognition The Company is in the business of performing drug testing services and reporting the results thereof. The Company's services are primarily drug and alcohol testing for its customers for an agreed-upon fee per unit tested. The revenues are recognized when the drug test is performed and reported to the customer. On January 1, 2018, 606, “Revenue from Contracts with Customers” 606” 606 not Revenue is recognized when control of the services is transferred to our customers, in an amount that reflects the consideration ( none 30 60 The table below disaggregates our external revenue by major source (in thousands). For additional revenue detail relating to geographic breakdown of sales, see Note 14 Year Ended December 31, 2020 2019 2018 Consolidated Revenue: Testing $ 19,068 $ 34,555 $ 39,174 Shipping / Collection (hair) 2,174 2,876 3,159 Other 118 247 341 Total Revenue $ 21,360 $ 37,678 $ 42,674 Testing Revenue Drug and alcohol tests for drugs of abuse using hair, performed in the Company's forensic laboratory in California, represents our primary service. Sales to customers are initiated through sales agreements, most of which have standard terms. Most tests are identified through a chain of custody form (“CCF”) and can therefore be uniquely tracked. Revenue is recognized when performance obligations under the terms of the contract with a customer are satisfied; generally, this occurs with the transfer of control of our service, which occurs at a specific point-in-time. The specific point-in-time is the completion of the test and availability of test results to the customer. Most tests are completed the same day that the hair specimen is received. Substantially all tests are completed within a few days once received for processing at our laboratory in California. As the tests are performed in a forensic laboratory, the exact date and time of each test completion is available and used in the timing of recognition of revenue. Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. Sales taxes the Company pays concurrent with revenue-producing activities are excluded from revenue. Shipping and Hair Collection Revenue Shipping revenue represents the amount billed to customers related to shipping of the hair specimen and CCF (“sample”) to the Company's laboratory. Collection revenue represents the amount billed to customers related to the collection of the hair specimen. This collection is done by third Revenue is measured as the amount of consideration the Company expects to receive in exchange for providing services. As the Company controls the service before transferring to the customer, it is considered a principal in the transaction, and therefore records revenues on gross basis, with shipping and hair collection costs in costs of revenues. Other Revenue Other revenue represents several items including; urine testing performed by other labs, medical review officer charges, legal/testifying services, and other miscellaneous charges. The total of all of these items is less than 1% Practical Expedients and Exemptions The Company generally expenses sales commissions when incurred as they are typically not
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses The Company expenses all research and development costs as incurred.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes using the liability method pursuant to ASC 740, “Income Taxes”
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Off-Balance Sheet Risk The Company has no may not not not
Major Customers, Policy [Policy Text Block]	Significant Customers The Company had no 10% December 31, 2020. One 26% 31% December 31, 2019 2018, no 10% December 31, 2020. two 13% 11% December 31, 2019.
Share-based Payment Arrangement [Policy Text Block]	Stock-Based Compensation The Company accounts for equity awards in accordance with ASC 718, Compensation — Stock Compensation” 718” 718 one not 2016, 2016 09, Improvements to Employee Share-Based Payment Accounting no Stock compensation expense by income statement account is as follows (in thousands): Stock-Based Compensation Year Ended December 31, 2020 2019 2018 Cost of revenues $ 50 $ 59 $ 62 General & administrative 380 579 436 Marketing & selling 74 54 29 Research & development 59 67 67 Total stock compensation $ 563 $ 759 $ 594 See Note 7
Earnings Per Share, Policy [Policy Text Block]	Basic and Diluted Net Income per Share Basic net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted net income per share is computed by dividing net income available to common shareholders by the weighted average number of common shares and dilutive common stock equivalents outstanding during the period. The number of dilutive common stock equivalents outstanding during the period has been determined in accordance with the treasury-stock method. Common equivalent shares consist of common stock issuable upon the exercise of outstanding options and the unvested portion of stock unit awards (“SUAs”). Basic and diluted weighted average common shares outstanding are as follows (in thousands): 2020 2019 2018 Weighted average common shares outstanding, basic 5,524 5,514 5,502 Dilutive common equivalent shares - 11 45 Weighted average common shares outstanding, assuming dilution 5,524 5,525 5,547 For the years ended December 31, 2020, 2019 2018, 588 357 86 not
Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial Instruments Financial instruments include cash, accounts receivable and accounts payable. Estimated fair values of these financial instruments approximate carrying values due to their short-term nature. The Company has two 30 1.75% 3.79%. one 1%
Basis of Presentation and Consolidation, Policy [Policy Text Block]	Basis of Preparation and Consolidation The consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries have been prepared using accounting principles generally accepted in the United States (“U.S. GAAP”). All intercompany transactions and balances have been eliminated.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation To the extent sales are made through our Brazil subsidiary, such sales are transacted in Brazilian Real and translated into US dollars. Foreign currency denominated assets and liabilities are translated into U.S. dollars using the exchange rates in effect at the consolidated balance sheet date. Results of operations and cash flows are translated using the average exchange rates throughout the period. The effect of exchange rate fluctuations on translation of assets and liabilities that are in the functional currency is included as a component of shareholders' equity in accumulated other comprehensive income (loss). The total change in foreign currency translation adjustment for the year ended December 31, 2020 2019 $0.2 $0.2
Segment Reporting, Policy [Policy Text Block]	Segment Reporting The Company manages its operations as one 14
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Pronouncements In February 2016, 2016 02, Leases” 2018 10, 2018 11, 2018 20 2019 01 842 12 December 15, 2018 842 January 1, 2019 ( 10 In August 2018, 2018 15, Intangibles—Goodwill and Other—Internal-Use Software: Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” 2018 15 2018 15 2020, 2018 15 January 1, 2019 no New Accounting Pronouncements In December 2019, 2019 12, Income Taxes (Topic 740 740. 740 December 15, 2020, may

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Property, Plant and Equipment [Table Text Block]	Computer software (years) 3 to 5 Office furniture and equipment (years) 3 to 7 Laboratory equipment 5 to 7 Leasehold improvements Lesser of estimated useful life or lease term
Disaggregation of Revenue [Table Text Block]	Year Ended December 31, 2020 2019 2018 Consolidated Revenue: Testing $ 19,068 $ 34,555 $ 39,174 Shipping / Collection (hair) 2,174 2,876 3,159 Other 118 247 341 Total Revenue $ 21,360 $ 37,678 $ 42,674
Schedule of Stock Based Compensation Expense [Table Text Block]	Stock-Based Compensation Year Ended December 31, 2020 2019 2018 Cost of revenues $ 50 $ 59 $ 62 General & administrative 380 579 436 Marketing & selling 74 54 29 Research & development 59 67 67 Total stock compensation $ 563 $ 759 $ 594
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	2020 2019 2018 Weighted average common shares outstanding, basic 5,524 5,514 5,502 Dilutive common equivalent shares - 11 45 Weighted average common shares outstanding, assuming dilution 5,524 5,525 5,547

Note 3 - Accounts Receivable (T

Note 3 - Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Financing Receivable, Current, Allowance for Credit Loss [Table Text Block]	As of December 31, 2020 2019 Balance, beginning of period $ 45 $ 67 Provision for doubtful accounts 22 11 Write-offs (30 ) (33 ) Balance, end of period $ 37 $ 45

Note 4 - Accrued Expenses (Tabl

Note 4 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Accrued Liabilities [Table Text Block]	As of December 31, 2020 2019 Accrued compensation and employee benefits $ 315 $ 450 Accrued vacation expense 379 399 Accrued taxes 4 564 Accrued shipping expense 511 368 Accrued payables for equipment and leasehold improvements - 1,453 Other accrued expenses 592 343 Total Accrued Expenses $ 1,801 $ 3,577

Note 5 - Income Taxes (Tables)

Note 5 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Year Ended December 31, 2020 2019 2018 Current – Federal $ (2,006 ) $ 1,478 $ 2,117 State (2 ) 54 119 Foreign - 348 1,122 Total Current Deferred – (2,008 ) 1,880 3,358 Federal (13 ) (139 ) (168 ) State (326 ) (227 ) (121 ) Total Deferred (339 ) (366 ) (289 ) Income Tax Provision $ (2,347 ) $ 1,514 $ 3,069
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	Year Ended December 31, 2020 2019 2018 Federal statutory rate 21.0 % 21.0 % 21.0 % State income taxes, net of federal benefit 4.4 % (4.5 %) 0.0 % Permanent differences 0.0 % (8.1 %) 0.2 % Stock based compensation (0.4 %) 1.3 % 0.1 % Federal R&D Credits 1.6 % (4.7 %) (1.7 %) Foreign taxes, net of federal benefit (2.2 %) 44.5 % 20.5 % Difference in tax rate for carryback claim 13.4 % 0.0 % 0.0 % Effective tax rate 37.8 % 49.5 % 40.1 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2020 2019 Deferred Tax Assets Allowance for doubtful accounts $ 9 $ 10 Accrued expenses 112 87 Stock-based compensation 265 195 R&D tax credits 1,005 788 Operating lease 1,130 764 PPP Loan expenses 9 - NOL Carryforward 97 - Total Deferred Tax Assets $ 2,627 $ 1,844 Deferred Tax Liabilities Excess of tax over book depreciation and amortization $ (1,775 ) $ (1,696 ) Prepaid expenses (48 ) (40 ) Operating lease (1,015 ) (658 ) Total Deferred Tax Liabilities (2,838 ) (2,394 ) Net Deferred Tax Liabilities $ (211 ) $ (550 )

Note 7 - Stock-based Awards (Ta

Note 7 - Stock-based Awards (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]	Grant Date Type Shares Fair Value (1) December 16, 2020 SUA 5 $ 4.71 November 11, 2020 Options 40 $ 1.13 November 11, 2020 SUA 190 $ 4.07 May 3, 2019 Options 192 $ 2.99 May 3, 2019 SUA 18 $ 10.60 July 24, 2018 Options 2 $ 5.49 May 3, 2018 SUA 6 $ 21.04 May 3, 2018 Options 117 $ 5.69
Share-based Payment Arrangement, Option, Activity [Table Text Block]	Number of Shares Weighted Average Exercise Price Per Share Weighted Average Remaining Contractual Life (years) Aggregate Intrinsic Value (2) Outstanding, December 31, 2019 584 $ 14.94 7.9 $ - Granted 40 $ 4.14 Exercised - - Forfeited (20 ) $ 3.21 Outstanding, December 31, 2020 604 $ 14.31 7.0 $ - Exercisable, December 31, 2020 424 $ 14.55 6.7 $ 35
Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]	Weighted Weighted Number of Average Price Average Fair Shares per Share (3) Value (3) Outstanding & Unvested, December 31, 2019 24 $ 12.84 $ 311 Granted 195 $ 4.07 $ 794 Converted to common stock (20 ) $ 13.00 $ (254 ) Cancelled (1 ) $ 20.24 $ (20 ) Forfeited (32 ) $ 5.12 $ (162 ) Outstanding & Unvested, December 31, 2020 166 $ 4.50 $ 745

Note 10 - Operating Leases (Tab

Note 10 - Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Lessee, Operating Lease, Liability, Maturity [Table Text Block]	2021 $ 1,041 2022 1,028 2023 1,096 2024 1,035 2025 593 2026 458 Total Lease Payments 5,251 Less Interest: (481 ) Present value of lease liabilities $ 4,770 Current operating lease liabilities $ 875 Long-term operating lease liabilities 3,895 Total $ 4,770

Note 11 - Debt and Other Fina_2

Note 11 - Debt and Other Financing Arrangements (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Schedule of Long-term Debt Instruments [Table Text Block]	2021 $ 688 2022 664 2023 294 2024 305 Long-term debt from equipment financing 1,951 Less current portion of long-term debt from equipment financing (688 ) Long-term debt from equipment financing, net of current portion 1,263 PPP Loan 2,181 Total long-term debt, net of current portion $ 3,444

Note 12 - Selected Quarterly _2

Note 12 - Selected Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Quarterly Financial Information [Table Text Block]	Quarter Ended - 2020 MAR 31 JUN 30 SEP 30 DEC 31 Revenues $ 7,537 $ 3,314 $ 5,174 $ 5,335 Gross profit 2,728 (252 ) 1,133 1,277 Loss from operations (242 ) (3,306 ) (1,409 ) (1,109 ) Net loss (159 ) (2,050 ) (1,107 ) (543 ) Basic net loss per share $ (0.03 ) $ (0.37 ) $ (0.20 ) $ (0.10 ) Diluted net loss per share $ (0.03 ) $ (0.37 ) $ (0.20 ) $ (0.10 ) Quarter Ended - 2019 MAR 31 JUN 30 SEP 30 DEC 31 Revenues $ 9,822 $ 9,289 $ 9,852 $ 8,715 Gross profit 4,408 4,169 4,382 3,485 Income (loss) from operations 944 1,326 1,334 (606 ) Net income (loss) 627 768 677 (530 ) Basic net income (loss) per share $ 0.11 $ 0.14 $ 0.12 $ (0.09 ) Diluted net income (loss) per share $ 0.11 $ 0.14 $ 0.12 $ (0.09 )

Note 14 - Business Segment Re_2

Note 14 - Business Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2020
Notes Tables
Revenue from External Customers by Geographic Areas [Table Text Block]	Year Ended December 31, 2020 2019 2018 Consolidated Revenue: United States $ 19,486 $ 27,329 $ 29,189 Brazil 1,344 9,819 13,046 Other 530 530 439 Total Revenue $ 21,360 $ 37,678 $ 42,674
Schedule of Segment Reporting Information, by Segment [Table Text Block]	As of December 31, Assets: 2020 2019 United States $ 24,003 $ 27,091 Brazil - 440 Total Assets $ 24,003 $ 27,531

Note 1 - Nature of Business (De

Note 1 - Nature of Business (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Benefit CARES Act	$ 2,100
Cash and Cash Equivalents, at Carrying Value, Ending Balance	$ 2,833	$ 7,283

Note 2 - Summary of Significa_3

Note 2 - Summary of Significant Accounting Policies (Details Textual) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)shares
Cash Equivalents, at Carrying Value, Total	$ 0	$ 0
Depreciation, Depletion and Amortization, Nonproduction, Total	2,600	2,900	$ 3,100
Property, Plant and Equipment, Net, Ending Balance	$ 9,231	$ 10,862
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares	588	357	86
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent, Total		$ (200)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax		$ (200)
Number of Operating Segments	1
Equipment Loan Arrangement [Member]
Debt Instrument, Interest Rate, Stated Percentage	3.79%
Equipment Loan Arrangement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate	1.75%
Paycheck Protection Program CARES Act [Member]
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Credit Concentration Risk [Member] | Revenue Benchmark [Member]
Number of Major Customers	0	1	1
Credit Concentration Risk [Member] | Revenue Benchmark [Member] | Customer One [Member]
Concentration Risk, Percentage		26.00%	31.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member]
Number of Major Customers	0	2
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]
Concentration Risk, Percentage		13.00%
Credit Concentration Risk [Member] | Accounts Receivable [Member] | Customer Two [Member]
Concentration Risk, Percentage		11.00%
Patents [Member]
Amortization, Total	$ 62	$ 40	$ 38
Finite-Lived Intangible Asset, Useful Life (Year)	20 years
Legal Cost Capitalized	$ 1,000	1,000
Legal Cost Capitalized, Amortization	300	300
Legal Cost Capitalized, Net	700	700
Patents [Member] | Maximum [Member]
Finite-Lived Intangible Asset, Expected Amortization, Year One	65
Capitalized Software and Equipment [Member]
Property, Plant and Equipment, Net, Ending Balance	$ 800
Software Development [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
Software Development Cost Capitalized	$ 213	234
Amortization, Total	$ 293	$ 457	$ 525

Note 2 - Summary of Significa_4

Note 2 - Summary of Significant Accounting Policies - Summary of Useful Lives of Assets (Details)	12 Months Ended
	Dec. 31, 2020
Minimum [Member] | Office Equipment [Member]
Property, plant and equipment, useful life (Year)	3 years
Minimum [Member] | Laboratory Equipment [Member]
Property, plant and equipment, useful life (Year)	5 years
Minimum [Member] | Computer Software, Intangible Asset [Member]
Property, plant and equipment, useful life (Year)	3 years
Maximum [Member] | Office Equipment [Member]
Property, plant and equipment, useful life (Year)	7 years
Maximum [Member] | Laboratory Equipment [Member]
Property, plant and equipment, useful life (Year)	7 years
Maximum [Member] | Computer Software, Intangible Asset [Member]
Property, plant and equipment, useful life (Year)	5 years

Note 2 - Summary of Significa_5

Note 2 - Summary of Significant Accounting Policies - Revenue by Major Source (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues	$ 5,335	$ 5,174	$ 3,314	$ 7,537	$ 8,715	$ 9,852	$ 9,289	$ 9,822	$ 21,360	$ 37,678	$ 42,674
Testing [Member]
Revenues									19,068	34,555	39,174
Shipping/Collection (Hair) [Member]
Revenues									2,174	2,876	3,159
Other Revenue [Member]
Revenues									$ 118	$ 247	$ 341

Note 2 - Summary of Significa_6

Note 2 - Summary of Significant Accounting Policies - Summary of Stock Compensation Expense by Income Statement Account (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Stock compensation expense	$ 563	$ 759	$ 594
Cost of Sales [Member]
Stock compensation expense	50	59	62
General and Administrative Expense [Member]
Stock compensation expense	380	579	436
Selling and Marketing Expense [Member]
Stock compensation expense	74	54	29
Research and Development Expense [Member]
Stock compensation expense	$ 59	$ 67	$ 67

Note 2 - Summary of Significa_7

Note 2 - Summary of Significant Accounting Policies - Basic and Diluted Weighted Average Common Shares Outstanding (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Weighted average common shares outstanding, basic (in shares)	5,524	5,514	5,502
Dilutive common equivalent shares (in shares)		11	45
Weighted average common shares outstanding, assuming dilution (in shares)	5,524	5,525	5,547

Note 3 - Accounts Receivable -

Note 3 - Accounts Receivable - Summary of the Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Balance, beginning of period	$ 45	$ 67
Provision for doubtful accounts	22	11
Write-offs	(30)	(33)
Balance, end of period	$ 37	$ 45

Note 4 - Accrued Expenses - Sum

Note 4 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Accrued compensation and employee benefits	$ 315	$ 450
Accrued vacation expense	379	399
Accrued taxes	4	564
Accrued shipping expense	511	368
Accrued payables for equipment and leasehold improvements		1,453
Other accrued expenses	592	343
Total Accrued Expenses	$ 1,801	$ 3,577

Note 5 - Income Taxes (Details

Note 5 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent	4.40%	(4.50%)	0.00%
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent	(1.60%)	4.70%	1.70%
Liability for Uncertainty in Income Taxes, Current		$ 0
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total	$ (6,206)	3,056	$ 7,653
BRAZIL
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Total		$ (1,100)
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards, Total	0
Tax Credit Carryforward, Amount	100
State and Local Jurisdiction [Member]
Operating Loss Carryforwards, Total	1,700
State and Local Jurisdiction [Member] | California Franchise Tax Board [Member]
Tax Credit Carryforward, Amount	$ 1,100
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent	1.80%

Note 5 - Income Taxes - Summary

Note 5 - Income Taxes - Summary of Income Tax Provision (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Federal	$ (2,006)	$ 1,478	$ 2,117
State	(2)	54	119
Foreign		348	1,122
Total Current Deferred –	(2,008)	1,880	3,358
Federal	(13)	(139)	(168)
State	(326)	(227)	(121)
Total Deferred	(339)	(366)	(289)
Income Tax Provision	$ (2,347)	$ 1,514	$ 3,069

Note 5 - Income Taxes - Reconci

Note 5 - Income Taxes - Reconciliation of Effective Rate with Federal Statutory Rate (Details)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Federal statutory rate	21.00%	21.00%	21.00%
State income taxes, net of federal benefit	4.40%	(4.50%)	0.00%
Permanent differences	0.00%	(8.10%)	0.20%
Stock based compensation	(0.40%)	1.30%	0.10%
Federal R&D Credits	1.60%	(4.70%)	(1.70%)
Foreign taxes, net of federal benefit	(2.20%)	44.50%	20.50%
Difference in tax rate for carryback claim	13.40%	0.00%	0.00%
Effective tax rate	37.80%	49.50%	40.10%

Note 5 - Income Taxes - Compone

Note 5 - Income Taxes - Components of Net Deferred Tax Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Deferred Tax Assets
Allowance for doubtful accounts	$ 9	$ 10
Accrued expenses	112	87
Stock-based compensation	265	195
R&D tax credits	1,005	788
Operating lease	1,130	764
PPP Loan expenses	9
NOL Carryforward	97
Total Deferred Tax Assets	2,627	1,844
Deferred Tax Liabilities
Excess of tax over book depreciation and amortization	(1,775)	(1,696)
Prepaid expenses	(48)	(40)
Operating lease	(1,015)	(658)
Total Deferred Tax Liabilities	(2,838)	(2,394)
Net Deferred Tax Liabilities	$ (211)	$ (550)

Note 7 - Stock-based Awards (De

Note 7 - Stock-based Awards (Details Textual) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	Dec. 16, 2020	Nov. 11, 2020	May 03, 2019	Jul. 24, 2018	May 03, 2018	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2006	Jan. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		40				40
Share Price (in dollars per share)		$ 1.13	$ 2.99	$ 5.49	$ 5.69	$ 5.09	$ 9.15
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)				21.04		$ 3.47	$ 3.40	$ 2.49
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value						$ 274	$ 223	$ 308
Conversion of Stock, Amount Issued						$ 115	$ 144	$ 493
Stock Unit Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	5	190				195
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)						$ 4.89	$ 12.01	$ 14.42
Stock Unit Award [Member] | Share-based Payment Arrangement, Nonemployee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	2 years
Stock Unit Award [Member] | Share-based Payment Arrangement, Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	4 years
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)		$ 4.07	$ 10.60	$ 19.83
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)				6 years 91 days
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		45.00%	41.00%	39.00%	38.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		0.90%	2.40%	3.40%	3.40%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate		4.00%	3.90%	4.10%	4.20%
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total						$ 1,100
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)						3 years 36 days
Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Nonemployee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	2 years
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)						2 years
Minimum [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)		5 years 273 days	5 years 273 days		5 years 273 days
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)						4 years
Maximum [Member] | Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)		6 years 91 days	6 years 91 days		6 years 91 days
Maximum [Member] | Share-based Payment Arrangement, Option [Member] | Share-based Payment Arrangement, Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	4 years
Incentive Plan 2006 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)									10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)						45			850	1,200
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)						0
Common Stock, Capital Shares Reserved for Future Issuance (in shares)						815

Note 7 - Stock-based Awards - S

Note 7 - Stock-based Awards - Summary of Shares Granted Under the 2006 Incentive Plan (Details) - $ / shares		Nov. 11, 2020	Dec. 31, 2020
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		40,000	40,000
Fair value per share (in dollars per share)			$ 4.14
December 16, 2020 [Member] | Stock Unit Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			5,000
Fair value per share (in dollars per share)	[1]		$ 4.71
November 11, 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			40,000
Fair value per share (in dollars per share)	[1]		$ 1.13
November 11, 2020 [Member] | Stock Unit Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			190,000
Fair value per share (in dollars per share)	[1]		$ 4.07
May 3, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			192,000
Fair value per share (in dollars per share)	[1]		$ 2.99
May 3, 2019 [Member] | Stock Unit Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			18,000
Fair value per share (in dollars per share)	[1]		$ 10.60
July 24, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			2,000
Fair value per share (in dollars per share)	[1]		$ 5.49
May 3, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			117
Fair value per share (in dollars per share)			$ 5.69
May 3, 2018 [Member] | Stock Unit Award [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)			6,000
Fair value per share (in dollars per share)	[1]		$ 21.04
[1]	The fair value for the SUA's is the closing price of the Company's stock on that date. The fair value for options represents the fair value calculated using the Black-Scholes model. Options have contractual lives of 10 years. The options granted on May 3, 2018 have a fair value of $5.69 per share based on the $21.04 grant date and exercise prices and assuming 6.25 and 5.75 year estimated terms, 38% volatility, 3.4% interest rate and a 4.2% dividend yield rate. The options granted on July 24, 2018 have a fair value of $5.49 per share based on the $19.83 grant date and exercise prices and assuming a 6.25 year estimated term, 39% volatility, 3.4% interest rate and a 4.1% dividend yield rate. The options granted on May 3, 2019 have a fair value of $2.99 per share based on the $10.60 grant date and exercise prices and assuming 6.25 and 5.75 year estimated terms, 41% volatility, 2.4% interest rate and a 3.9% dividend yield rate. The options granted on November 11, 2020 have a fair value of $1.13 per share based on the $4.07 grant date and exercise prices and assuming 6.25 and 5.75 year estimated terms, 45% volatility, 0.9% interest rate and a 4.0% dividend yield rate. For options granted during fiscal years ended December 31, 2020, 2019, and 2018, the weighted average grant date fair values were $3.47, $3.40 and $2.49, respectively. For SUAs granted during fiscal years ended December 31, 2020, 2019, and 2018, the weighted average grant date fair values were $4.89, $12.01 and $14.42, respectively.

Note 7 - Stock-based Awards -_2

Note 7 - Stock-based Awards - Stock Option Activity (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		Nov. 11, 2020	Dec. 31, 2020	Dec. 31, 2019
Outstanding (in shares)			584
Outstanding, weighted average exercise price (in dollars per share)			$ 14.94
Outstanding, weighted average remaining contractual life (Year)			7 years	7 years 328 days
Outstanding, aggregate intrinsic value	[1]
Granted (in shares)		40	40
Granted, weighted average exercise price (in dollars per share)			$ 4.14
Exercised (in shares)
Exercised, weighted average exercise price (in dollars per share)
Forfeited (in shares)			(20)
Forfeited, weighted average exercise price (in dollars per share)			$ 3.21
Outstanding (in shares)			604	584
Outstanding, weighted average exercise price (in dollars per share)			$ 14.31	$ 14.94
Exercisable (in shares)			424
Exercisable, weighted average exercise price (in dollars per share)			$ 14.55
Exercisable, weighted average remaining contractual life (Year)			6 years 255 days
Exercisable, aggregate intrinsic value	[1]		$ 35
[1]	The aggregate intrinsic value on this table was calculated based on the amount, if any, by which the closing market price of the Company's stock on December 31 of the applicable year exceeded the exercise price of any of the underlying options, multiplied by the number of shares subject to each such option. The closing stock price as of December 31, 2020 and 2019 was $5.09 and $9.15, respectively.

Note 7 - Stock-based Awards - N

Note 7 - Stock-based Awards - Nonvested Award Activity (Details) - Stock Unit Award [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		Dec. 16, 2020	Nov. 11, 2020	Dec. 31, 2020
Outstanding & Unvested at beginning of period (in shares)				24
Outstanding & Unvested at end of period, weighted average price per share (in dollars per share)	[1]			$ 12.84
Outstanding & Unvested at beginning of period, weighted average fair value	[1]			$ 311
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)		5	190	195
Granted, weighted average price per share (in dollars per share)	[1]			$ 4.07
Granted, weighted average fair value	[1]			$ 794
Converted to common stock (in shares)				(20)
Converted to common stock, weighted average price per share (in dollars per share)	[1]			$ 13
Converted to common stock, weighted average fair value	[1]			$ (254)
Cancelled (in shares)				(1)
Cancelled, weighted average price per share (in dollars per share)	[1]			$ 20.24
Cancelled, weighted average fair value	[1]			$ (20)
Forfeited (in shares)				(32)
Forfeited, weighted average price per share (in dollars per share)	[1]			$ 5.12
Forfeited, weighted average fair value	[1]			$ (162)
Outstanding & Unvested at end of period (in shares)				166
Outstanding & Unvested at end of period, weighted average price per share (in dollars per share)	[1]			$ 4.50
Outstanding & Unvested at end of period, weighted average fair value	[1]			$ 745
[1]	Weighted average price per share is the weighted grant price based on the closing market price of each of the stock grants related to each transaction type. The weighted average fair value is the weighted average share price times the number of shares.

Note 8 - Employee Benefit Plan

Note 8 - Employee Benefit Plan (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 198	$ 262	$ 264

Note 9 - Commitments and Cont_2

Note 9 - Commitments and Contingencies (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Operating Leases, Rent Expense, Total	$ 1.1	$ 1.2	$ 1

Note 10 - Operating Leases (Det

Note 10 - Operating Leases (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Operating Lease, Right-of-Use Asset	$ 4,286	$ 2,875
Operating Lease, Liability, Total	$ 4,770	3,300
Operating Lease, Weighted Average Discount Rate, Percent	3.90%
Operating Lease, Weighted Average Remaining Lease Term (Year)	4 years 328 days
Operating Lease, Expense	$ 1,100	$ 1,200

Note 10 - Operating Leases - Ma

Note 10 - Operating Leases - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
2021	$ 1,041
2022	1,028
2023	1,096
2024	1,035
2025	593
2026	458
Total Lease Payments	5,251
Less Interest:	(481)
Present value of lease liabilities	4,770	$ 3,300
Current operating lease liabilities	875	963
Long-term operating lease liabilities	3,895	2,375
Total	$ 4,770	$ 3,300

Note 11 - Debt and Other Fina_3

Note 11 - Debt and Other Financing Arrangements (Details Textual) - USD ($)	Mar. 23, 2021	Nov. 02, 2020	May 01, 2020	Dec. 04, 2019	Dec. 02, 2019	Nov. 10, 2017	Oct. 30, 2017	Mar. 23, 2016	Sep. 15, 2015	Aug. 08, 2014	Jun. 13, 2014	May 22, 2014	Mar. 24, 2014	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 04, 2019
Interest Expense, Total														$ 75,000	$ 59,000	$ 106,000
Equipment Loan Arrangement [Member]
Debt Instrument, Interest Rate, Stated Percentage														3.79%
Proceeds from Issuance of Long-term Debt, Total															1,416,000
Equipment Loan Arrangement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate														1.75%
Paycheck Protection Program CARES Act [Member]
Debt Instrument, Interest Rate, Stated Percentage														1.00%
Proceeds from Issuance of Long-term Debt, Total			$ 2,181,157											$ 2,181,000
Banc of America Leasing and Capital [Member] | Equipment Loan Arrangement [Member] | Line of Credit [Member]
Interest Expense, Total					$ 16,000,000									75,000
Debt Instrument, Term (Month)					5 years
Debt Instrument, Interest Rate, Stated Percentage					3.79%
Debt Instrument, Covenant, Cash and Certain Cash Equivalents, Minimum		$ 1,500,000
Debt Instrument, Covenant, Minimum EBITDA for Fourth Quarter of 2020		1
Debt Instrument, Covenant, Minimum EBITDA for First Quarter of 2021		225,000
Debt Instrument, Collateral Amount														3,100,000
Proceeds from Issuance of Long-term Debt, Total				$ 1,400,000		$ 2,100,000		$ 610,000	$ 1,100,000	$ 1,000,000	$ 3,000,000	$ 1,900,000	$ 1,100,000				$ 12,200,000
Repayments of Long-term Debt, Total														$ 700,000	$ 400,000
Debt Instrument, Interest Rate During Period														3.00%
Debt, Weighted Average Interest Rate														3.00%
Debt Instrument, Covenant, Minimum EBITDA for Second Quarter of 2021		$ 225,000
Banc of America Leasing and Capital [Member] | Equipment Loan Arrangement [Member] | Line of Credit [Member] | Subsequent Event [Member]
Debt Instrument, Covenant, Minimum EBITDA for First Quarter of 2021	$ 1
Banc of America Leasing and Capital [Member] | Equipment Loan Arrangement [Member] | Line of Credit [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument, Basis Spread on Variable Rate							1.75%

Note 11 - Debt and Other Fina_4

Note 11 - Debt and Other Financing Arrangements - Schedule of Debt Repayments (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Less current portion of long-term debt from equipment financing	$ (688,000)	$ (678,000)
Total long-term debt, net of current portion	3,444,000	$ 1,951,000
Equipment Loan Arrangement [Member]
2021	688,000
2022	664,000
2023	294,000
2024	305,000
Long-term debt from equipment financing	1,951,000
Less current portion of long-term debt from equipment financing	(688)
Total long-term debt, net of current portion	1,263,000
Paycheck Protection Program CARES Act [Member]
Total long-term debt, net of current portion	$ 2,181,000

Note 12 - Selected Quarterly _3

Note 12 - Selected Quarterly Financial Data (Unaudited) - Selected Quarterly Financial Information (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues	$ 5,335	$ 5,174	$ 3,314	$ 7,537	$ 8,715	$ 9,852	$ 9,289	$ 9,822	$ 21,360	$ 37,678	$ 42,674
Gross profit	1,277	1,133	(252)	2,728	3,485	4,382	4,169	4,408	4,886	16,444	20,618
Income (loss) from operations	(1,109)	(1,409)	(3,306)	(242)	(606)	1,334	1,326	944	(6,066)	2,998	7,610
Net income (loss)	$ (543)	$ (1,107)	$ (2,050)	$ (159)	$ (530)	$ 677	$ 768	$ 627	$ (3,859)	$ 1,542	$ 4,584
Basic net income (loss) per share (in dollars per share)	$ (0.10)	$ (0.20)	$ (0.37)	$ (0.03)	$ (0.09)	$ 0.12	$ 0.14	$ 0.11	$ (0.70)	$ 0.28	$ 0.83
Diluted net income (loss) per share (in dollars per share)	$ (0.10)	$ (0.20)	$ (0.37)	$ (0.03)	$ (0.09)	$ 0.12	$ 0.14	$ 0.11	$ (0.70)	$ 0.28	$ 0.83

Note 13 - Other Expense (Detail

Note 13 - Other Expense (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Interest Expense, Total	$ 75	$ 59	$ 106
Interest Income, Other	$ 0	$ 134	$ 149

Note 14 - Business Segment Re_3

Note 14 - Business Segment Reporting (Details Textual)	12 Months Ended
	Dec. 31, 2020
Number of Operating Segments	1
Customer Concentration Risk [Member] | Revenue Benchmark [Member] | BRAZIL
Number of Major Customers	1

Note 14 - Business Segment Re_4

Note 14 - Business Segment Reporting - Revenue by Major Source (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues	$ 5,335	$ 5,174	$ 3,314	$ 7,537	$ 8,715	$ 9,852	$ 9,289	$ 9,822	$ 21,360	$ 37,678	$ 42,674
UNITED STATES
Revenues									19,486	27,329	29,189
BRAZIL
Revenues									1,344	9,819	13,046
Other Foreign Countries [Member]
Revenues									$ 530	$ 530	$ 439

Note 14 - Business Segment Re_5

Note 14 - Business Segment Reporting - Assets By Geographic Segment (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
Assets	$ 24,003	$ 27,531
UNITED STATES
Assets	24,003	27,091
BRAZIL
Assets		$ 440